Print

NUCRYST Pharmaceuticals Corp. (WEDX) Announces Management Realignment and R&D Portfolio Change; Discontinued Development of NPI 32101 for Inflammatory Bowel Disease (IBD)  
4/30/2008 3:01:53 PM

WAKEFIELD, MA, April 30 /CNW/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that the Company has realigned its management team to further advance its cost reduction and growth strategies. The realignment results in increased management responsibilities for David C. McDowell, Vice President Operations and the appointment of Edward Gaj, Jr., RPh to the newly created position of Vice President Marketing.
//-->